Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
Clinical Pharmacology of Asciminib: A Review.
Journal: Clinical pharmacokinetics
Published: September 06, 2024
Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation.
Journal: Clinical pharmacokinetics
Published: August 09, 2024
Correction to: Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases.
Journal: Clinical pharmacokinetics
Published: August 17, 2022
Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases.
Journal: Clinical pharmacokinetics
Published: May 29, 2022
Exposure-Efficacy Analysis of Asciminib in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase.
Journal: Clinical pharmacology and therapeutics
Published: March 22, 2022
Species difference in paclitaxel disposition correlated with poor pharmacological efficacy translation from mice to humans.
Journal: Clinical pharmacology : advances and applications
Published: December 07, 2018
Ghrelin-immunopositive hypothalamic neurons tie the circadian clock and visual system to the lateral hypothalamic arousal center.
Journal: Molecular metabolism
Published: January 01, 2012
Showing 1-7 of 7
Last Updated: 09/26/2026